These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 15985006)

  • 1. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
    J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
    J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
    de Vries-Sluijs TE; van der Eijk AA; Hansen BE; Osterhaus AD; de Man RA; van der Ende ME
    J Clin Virol; 2006 May; 36(1):60-3. PubMed ID: 16418013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
    Leemans WF; Janssen HL; Niesters HG; de Man RA
    J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
    HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G; Ratcliffe L; Vilar J
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
    J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between hepatitis B virus YMDD mutation and serum viral DNA loadings].
    Kong LH; Gao SX; Gui YP; Liu WH
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1262-3. PubMed ID: 17715043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
    Horiike N; Duong TN; Michitaka K; Joko K; Hiasa Y; Konishi I; Yano M; Onji M
    J Med Virol; 2007 Jul; 79(7):911-8. PubMed ID: 17516520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
    Wolters LM; van Nunen AB; Niesters HG; de Man RA
    Scand J Gastroenterol Suppl; 2000; (232):74-8. PubMed ID: 11232497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
    Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.